Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions

被引:5
|
作者
Klemencic Kozul, Tara [1 ]
Yudina, Anna [2 ]
Donovan, Carley [1 ]
Pinto, Ashwin [1 ]
Osman, Chinar [1 ]
机构
[1] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[2] Terumo Blood & Cell Technol Europe, Zaventem, Belgium
关键词
Plasma exchange (PLEX); Intravenous immunoglobulin (IVIg); Cost-minimisation; Autoimmune neurological disorders; Cost effectiveness; INTRAVENOUS IMMUNOGLOBULIN; ADVERSE EVENTS; PLASMAPHERESIS; COMPLICATIONS; SAFETY; GUIDELINES; APHERESIS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s12913-022-08210-z
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Plasma exchange (PLEX) is an effective treatment for antibody-mediated neurological disorders and has been shown to be equally efficacious to intravenous immunoglobulin (IVIg) with comparable adverse event profiles. IVIg has traditionally been the preferred treatment option due to its ease of use. However, advancing technology has allowed PLEX to be performed with a centrifugal system via peripheral access as opposed to central access via a membrane filter. Methods We prospectively collected data from a cohort of patients who underwent PLEX at the Wessex Neurological Centre, UK, to perform a cost-minimisation analysis comparing PLEX to IVIg, the standard of care, between May 2019 and May 2020. Data obtained included indication, admission type (inpatient, daycase or intensive care), access (peripheral or central), number of PLEX cycles, exchange volume, patient weight, complications and clinical outcomes. The cost of PLEX delivered in an outpatient setting for an average 80kg person was calculated and compared to the equivalent cost of delivering IVIg by means of a cost-minimization model. Results The provision of PLEX was roughly half as costly when compared to what it would have been for IVIg (886 pound per exchange vs 1778 pound per infusion or 4432 pound per cycle of 5 exchanges vs 8890 pound per cycle of 5 infusions). Our cohort included a total of 44 patients who received a total of 357 PLEX exchanges during the 12-month period (the majority of which were in a daycase setting). We calculated an annual cost saving for PLEX over IVIg of 318,589 pound. The robustness of this result was confirmed by a one-way deterministic sensitivity analysis, showing the cost-effectiveness of PLEX. Conclusion Our findings demonstrate that PLEX is more cost-effective than IVIg in this setting. Our study supports the economic case for development of plasma exchange centres in regional neurology units, a case made all the more relevant in the context of constrained supplies of IVIg.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Re: Economic evaluation of robot-assisted hysterectomy: a cost-minimisation analysis Reply
    Teljeur, C.
    O'Neill, M.
    Moran, P. S.
    Harrington, P.
    Murphy, L.
    Ryan, M.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 (05) : 754 - 755
  • [42] Cost-minimisation analysis of chronic lymphocytic leukemia in Spain in the era of oral targeted therapies
    Montanes, Belen
    Casado, Gema
    Medina, Angeles
    Nieto, Pablo
    Ramirez-Payer, Angel
    FARMACIA HOSPITALARIA, 2022, 46 (02) : 72 - 79
  • [43] A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting
    Bjorstad, Ase
    Cardell, Lars-Olaf
    Hahn-Pedersen, Julie
    Svard, Mikael
    CLINICAL DRUG INVESTIGATION, 2017, 37 (06) : 541 - 549
  • [44] High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient's satisfaction
    Maria Horta-Hernandez, Ana
    Esaclera-Izquierdo, Begona
    Yusta-Izquierdo, Antonio
    Martin-Alcalde, Eva
    Blanco-Crespo, Maria
    Alvarez-Nonay, Adriana
    Torralba, Miguel
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2019, 26 (05) : 280 - 284
  • [46] Treatment of autoimmune-related retinopathy and optic neuropathy syndrome (ARRON) with plasma exchange and IVIg
    Barrett, Rhonda V.
    Vaphiades, Michael S.
    NEURO-OPHTHALMOLOGY, 2008, 32 (01) : 33 - 39
  • [47] The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis
    Fretheim, A
    Aaserud, M
    Oxman, AD
    BMC HEALTH SERVICES RESEARCH, 2003, 3 (1)
  • [48] Cost-minimisation analysis of polysomnography and pulse oximetry in a risk stratification protocol for paediatric adenotonsillectomy
    Key, Seraphina
    Chia, Clemente
    Nixon, Gillian
    Paddle, Paul
    ANZ JOURNAL OF SURGERY, 2022, 92 (09) : 2292 - 2298
  • [49] A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting
    Åse Björstad
    Lars-Olaf Cardell
    Julie Hahn-Pedersen
    Mikael Svärd
    Clinical Drug Investigation, 2017, 37 : 541 - 549
  • [50] Association of antipsychotic polypharmacy with health service cost - a Danish register-based cost-minimisation analysis
    Baandrup, L.
    Sorensen, J.
    Lublin, H.
    Nordentoft, M.
    Glenthoj, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S460 - S461